유방암종의 HER2 종양단백의 면역조직화학적 발현

Abstract

Immunohistochemistry (IHC) is very simple method to evaluate the HER2 status in breast carcinoma. The aim of this study was to determine the potential value of the immunohistochemistry(IHC) using CB11 monoclonal antibody as a first-line screening of HER2 overexpression. The HER2 status of 198 consecutive cases of breast carcinoma was studied. Tissue arrays made from the representative portion of each breast carcinoma specimen were used for conventinal IHC using CB11 monoclonal antibody and HercepTest. Expression of HER2 of both methods was assessed by HercepTest scoring system of 0, 1+, 2+, and 3+. The result of IHC using CB11 monoclonal antibody correlated significantly with the HercepTest (concordance: 84.3%, kappa=0.704). It is highly suggested that IHC of CB11 monoclonal antibody can be used as a first-line test to explore the overexpression of HER2 by HercepTest.